Global Cardiac Biomarkers Testing Market Insights, Forecast to 2028

Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart.
Market Analysis and Insights: Global Cardiac Biomarkers Testing Market
The global Cardiac Biomarkers Testing market size is projected to reach US$ 11410 million by 2028, from US$ 7132.7 million in 2021, at a CAGR of 6.5% during 2022-2028.
Cardiac biomarkers are the substances released into the blood stream from the damaged muscle of the heart. These biomarkers are used to diagnose heart functioning, risk stratifications, and cardiac diseases in patients. Biomarker is a quantifiable and measurable biological parameter that includes an enzyme, hormones, and proteins, all associated with heart function, failure, or damage.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Cardiac Biomarkers Testing market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Cardiac Biomarkers Testing market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Cardiac Biomarkers Testing market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Cardiac Biomarkers Testing market.
Global Cardiac Biomarkers Testing Scope and Market Size
Cardiac Biomarkers Testing market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Cardiac Biomarkers Testing market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Myocardial Muscle Creatine Kinase (CK-MB)
Troponins (T and I)
Myoglobin
Brain Natriuretic Peptide (BNPs) or NT-proBNP
Ischemia-modified Albumin (IMA)
Others
Segment by Application
Myocardial Infarction
Congestive Heart Failure
Acute Coronary Syndrome
Atherosclerosis
Others
By Company
Abbott Laboratories
Becton, Dickinson and Company
BioMerieux
Bio-Rad Laboratories, Inc.
Danaher Corporation
ROCHE
Siemens AG
Thermo Fisher Scientific, Inc.
PerkinElmer Inc.
Tosoh Corporation
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA